BeiGene (BGNE)
(Delayed Data from NSDQ)
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BGNE 246.04 +12.40(5.31%)
Will BGNE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BGNE
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
Other News for BGNE
Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments
Chinese Biopharmaceutical Stocks Surge with Positive Policy Impact
Biotech Alert: Searches spiking for these stocks today
BeiGene: A Strong Buy on Robust R&D, Global Expansion, and Market Outperformance
Zymeworks Approaching A Moment Of Truth With Zanidatamab